BioXcel (BTAI) jumped after saying it received encouraging early FDA feedback ahead of an August 20 meeting on expanding Igalmi's use to at-home psychiatric care. The update follows completion of its pivotal Serenity At-Home Phase 3 trial, with top-line data due this quarter. Analysts see a larger commercial runway, with retail sentiment turning extremely bullish.